Displaying 1 - 2 of 2
| Active Ingredient | ABACAVIR |
| Therapeutic Class | NRTI |
| Indications |
Indicated in combination with other anti-HIV medications for the treatment of HIV-1 for adults and children. |
| Caution | Nausea, vomiting, fatigue, headache, diarrhoea and loss of appetite. Fatal lactic acidosis and severe hep atomegaly with steatosis have been reported. Fatal hypersensitivity reactions include s More ... |
| Dose Range | Adult: Recommended dosing is 300mg orally twice daily with or without food. Pediatric: 3 months - 16 years of age is 8mg/kg orally twice daily (up to a maximum of 300mg twice daily ). Abacavir should be used in combination with other antiretrovirals. |
| Drug Interactions | Alcohol reduces the metabolism of abacavir. |
| Pregnancy | The animal data suggest moderate risk. Although the human pregnancy experience d More ... |
| Breast Feeding | The Centers for Disease Control and Prevention (CDC) and other experts recommend More ... |
| Active Ingredient | ABACAVIR | LAMIVUDINE |
| Therapeutic Class | ANTIRETROVIRALS MISCELLANEOUS |
| Indications | HIV infection in combination with other antiretrovirals. |
| Caution | As for abacavir and lamivudine. |
| Dose Range | Adult:40 kg and over One tablet once daily . Abacavir/Lamivudine can be taken with or without food. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |